Drug Profile
Gallium-68 pasireotide - Ipsen
Alternative Names: 68Ga-pasireotide tetraxetan; Gallium-68-pasireotide tetraxetanLatest Information Update: 08 Nov 2018
Price :
$50
*
At a glance
- Originator Novartis
- Developer Ipsen
- Class Cyclic peptides; Imaging agents; Macrocyclic compounds; Oligopeptides; Radiopharmaceutical diagnostics
- Mechanism of Action Positron-emission tomography enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Neuroendocrine tumours
Most Recent Events
- 08 Nov 2018 Discontinued - Preclinical for Neuroendocrine tumours (Diagnosis) in Germany (IV)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Neuroendocrine-tumours(Diagnosis) in Germany (Parenteral)
- 27 Oct 2011 Preclinical trials in Neuroendocrine tumours (diagnosis) in Germany (IV)